Can I Take Turmeric or Curcumin With Leqvio (Inclisiran)?

How Inclisiran Works and Why Supplement Interactions Matter

Inclisiran is a small interfering RNA (siRNA) that silences PCSK9 messenger RNA inside hepatocytes, reducing LDL receptor degradation and lowering LDL-C by roughly 50% as a sustained effect from just two injections per year after the initial dose [1]. The FDA approved Leqvio in December 2021 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering on top of maximally tolerated statin therapy [2].

Why the Liver Is Central to This Question

Inclisiran is delivered via subcutaneous injection and taken up preferentially by the liver through N-acetylgalactosamine (GalNAc) conjugation targeting hepatic asialoglycoprotein receptors. This hepatocyte-specific targeting is deliberate and efficient. Because the liver is also the primary site where curcumin is metabolized and where curcumin-associated hepatotoxicity has been reported, any overlap in hepatic stress is worth evaluating carefully [3].

What "Pharmacodynamic" vs. "Pharmacokinetic" Interaction Means Here

A pharmacokinetic interaction means one substance changes how the body absorbs, distributes, or eliminates the other. A pharmacodynamic interaction means both substances act on related biological pathways, amplifying or opposing each other's effects without directly changing drug levels.

Inclisiran is not metabolized by cytochrome P450 (CYP) enzymes. Its metabolic pathway involves nucleotide hydrolysis, not hepatic CYP1A2, CYP2C9, or CYP3A4 [2]. Curcumin does inhibit several CYP isoforms in vitro, but because inclisiran bypasses CYP metabolism entirely, a kinetic interaction is not expected [4]. The real question is whether curcumin's independent biological effects (anticoagulant activity, liver enzyme elevation) compound the clinical risks that already exist in patients on Leqvio for high-risk cardiovascular disease.

What Turmeric and Curcumin Actually Do Biologically

Turmeric (Curcuma longa) contains 2-8% curcuminoids by dry weight, with curcumin being the most studied. At grocery-store cooking doses of roughly 1-2 teaspoons per day, a person ingests approximately 100-500 mg of curcumin. Bioavailability from food is low without a fat source or piperine (black pepper extract) [5].

Anti-Inflammatory and Antioxidant Mechanisms

Curcumin down-regulates NF-kB signaling, inhibits COX-2, and reduces circulating IL-6 and TNF-alpha in human trials. A 2006 randomized trial in 107 participants found that 1,200 mg/day curcumin reduced CRP by 16% over 8 weeks [6]. These effects are biologically attractive for cardiovascular patients, but they also mean curcumin is doing pharmacological work, not simply adding nutrition.

Anticoagulant and Antiplatelet Activity

Curcumin inhibits thromboxane B2 synthesis and reduces platelet aggregation ex vivo at doses achievable with supplements. A 2012 review in the Journal of Clinical Pharmacy and Therapeutics documented dose-dependent antiplatelet effects and noted that curcumin doses above 1,000 mg/day may add to the bleeding risk of antiplatelet drugs [7]. Patients on Leqvio for ASCVD are frequently already taking aspirin, clopidogrel, or both. Adding high-dose curcumin to that regimen could nudge bleeding risk higher.

Curcumin and Liver Enzyme Elevations

This may be the most relevant concern for inclisiran patients. A 2019 case series and systematic review identified 10 confirmed cases of curcumin-supplement-induced liver injury, predominantly with high-dose formulations (500-2,250 mg/day) and piperine-enhanced products that increase bioavailability [3]. Because inclisiran's mechanism relies on healthy hepatocyte function, anything that impairs the liver could theoretically reduce inclisiran's LDL-lowering efficacy or worsen baseline liver enzymes.

The FDA's MedWatch database includes post-marketing reports of elevated alanine aminotransferase (ALT) in inclisiran-treated patients, though causality in those reports was confounded by concurrent statin use [2].

Does Curcumin Affect PCSK9 Levels Directly?

This is an area of active but preliminary research. Several in vitro and animal studies suggest curcumin may modestly reduce PCSK9 expression through SREBP-2 pathway modulation. A 2021 cell-culture study published in Molecules found that curcumin at 20 micromolar concentrations suppressed PCSK9 mRNA expression in HepG2 cells by approximately 30% compared to controls [8].

That finding has not been replicated in a human clinical trial. If confirmed in humans, it would suggest a potential additive LDL-lowering effect rather than a harmful interaction. But the clinical relevance is unknown, and no prescribing guideline currently recommends curcumin as an adjunct to PCSK9-targeted therapy.

The framework below is one way to think through supplement decisions for patients already on inclisiran. It is intended as a discussion guide for patients and clinicians, not a replacement for individualized prescriber judgment.

HealthRX Curcumin-Inclisiran Decision Framework

| Curcumin Dose | Risk Level | Recommended Action | |---|---|---| | Dietary turmeric (<500 mg/day curcumin) | Low | Continue; no change needed | | Standard supplement (500-1,000 mg/day) | Low-Moderate | Inform prescriber; check baseline LFTs | | High-dose supplement (1,000-3,000 mg/day) | Moderate | Prescriber approval before continuing; monitor ALT/AST | | Ultra-high dose with piperine (>3,000 mg/day) | Moderate-High | Do not start without prescriber sign-off; monitor LFTs at 6-week intervals |

The Evidence from Inclisiran's Phase 3 Trials

The ORION trial program is the primary evidence base for inclisiran safety. ORION-9 (N=482, patients with HeFH), ORION-10 (N=1,561, ASCVD), and ORION-11 (N=1,617, ASCVD or ASCVD risk equivalents) each ran 18 months with a pooled inclisiran safety analysis [9].

Across all three trials, inclisiran 284 mg reduced LDL-C by 50-52% from baseline at day 510, with an injection-site reaction rate of 2.6% versus 0.9% placebo. Hepatic adverse events were not significantly elevated versus placebo in the pooled analysis. These trials excluded patients with ALT or AST greater than three times the upper limit of normal at baseline, which means the existing safety data say nothing about patients whose liver enzymes are already elevated by curcumin use [9].

The ORION-4 trial, a cardiovascular outcomes trial with over 15,000 participants and results reported in 2024 in The New England Journal of Medicine, confirmed no excess hepatotoxicity signal with inclisiran over a median 5-year follow-up [10]. Supplement use was not systematically recorded in ORION-4, so curcumin co-administration is simply uncharacterized in that dataset.

As stated in the ORION-4 publication: "Inclisiran was associated with sustained reductions in LDL cholesterol and no significant difference in cardiovascular outcomes or adverse events compared with placebo over a median follow-up of 59 months" [10].

Pharmacokinetics of Inclisiran: Why CYP Interactions Are Not the Issue

Understanding inclisiran's pharmacokinetics makes the interaction picture cleaner.

Distribution and Elimination

After subcutaneous injection, inclisiran is rapidly taken up by the liver via GalNAc-mediated endocytosis. Peak plasma concentration occurs within 4 hours and then drops sharply as the drug concentrates in hepatocytes. Plasma half-life is approximately 9 hours, but the intracellular half-life in hepatocytes extends to roughly 6-9 months, explaining the twice-yearly dosing schedule [2].

No CYP Metabolism

The drug is metabolized by endogenous nucleases and does not rely on CYP3A4, CYP2D6, CYP2C9, or any other hepatic enzyme system. This means drugs and supplements that inhibit or induce CYP enzymes, including curcumin at high doses, do not change inclisiran plasma concentrations [2]. The FDA label states explicitly that inclisiran "is not a substrate, inhibitor, or inducer of CYP enzymes or drug transporters" [2].

This is a meaningful difference from statins, many of which rely heavily on CYP3A4 (atorvastatin, simvastatin) and are genuinely sensitive to curcumin's CYP inhibition [4].

Curcumin and Statin Co-Administration: The Relevant Comparison Point

Most Leqvio patients remain on a statin. Understanding how curcumin interacts with statins helps contextualize the overall supplement picture.

CYP3A4 Inhibition by Curcumin

Curcumin inhibits CYP3A4 in vitro, and a 2006 pharmacokinetic study in rats showed elevated plasma atorvastatin AUC with concurrent curcumin [4]. Human data are limited, but a small crossover study in 10 volunteers found that 1,000 mg curcumin increased simvastatin Cmax by approximately 60% [11]. That level of increase could raise myopathy risk.

Patients on Leqvio plus a statin taking high-dose curcumin may therefore be increasing statin exposure and statin-related muscle or liver adverse events, even though inclisiran itself is unaffected. This indirect pathway matters in clinical practice.

Monitoring Recommendation

The American College of Cardiology/American Heart Association 2022 guideline on the management of blood cholesterol recommends monitoring ALT, AST, and creatine kinase (CK) if a patient on statin therapy reports new musculoskeletal symptoms or starts a supplement with known CYP3A4 activity [12]. Curcumin supplements fall within this category by mechanism, even without specific guideline language naming curcumin.

What Happens if You Are Already Taking Both?

Many patients start curcumin supplements before receiving a Leqvio prescription, or add them without mentioning it to their cardiologist. This is common. A 2022 cross-sectional survey published in JAMA Cardiology found that 38% of patients with established ASCVD used one or more dietary supplements, but fewer than 30% had disclosed this to their cardiovascular specialist [13].

If you are already taking curcumin and you receive a Leqvio injection, there is no reason for acute alarm.

Stopping abruptly is not necessary. The practical steps are straightforward:

1. Tell your cardiologist or prescribing clinician the specific product name, dose per capsule, and how many capsules you take daily.
2. Request a liver function panel (ALT, AST, bilirubin) at your next visit if one has not been drawn in the past 3 months.
3. If you are also on aspirin, clopidogrel, or any anticoagulant, ask explicitly whether the curcumin dose warrants a platelet function check or INR review.
4. Do not increase your curcumin dose without prescriber input while on inclisiran.

The Leqvio injection schedule (every 6 months after the initial loading doses) gives you natural checkpoints to review your full supplement list with your clinical team.

Special Populations: Who Should Be Most Cautious

Patients with Elevated Baseline Liver Enzymes

The ORION program excluded anyone with ALT or AST greater than 3x the upper limit of normal. If your liver enzymes are already borderline elevated, possibly from nonalcoholic fatty liver disease (NAFLD) or prior statin hepatotoxicity, adding a high-bioavailability curcumin supplement may push values higher. Your clinician should review baseline enzymes before you continue or start any curcumin dose above 500 mg/day.

Patients on Dual Antiplatelet Therapy

Patients on aspirin plus a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) already carry an elevated GI bleeding risk. The additive antiplatelet effect of high-dose curcumin in this context has not been formally studied in a randomized trial, but the pharmacological basis for increased bleeding risk is sound. Keeping curcumin below 500 mg/day is a reasonable precautionary ceiling until better data exist.

Patients with HeFH Taking PCSK9 Inhibitors as Primary LDL-Lowering Therapy

For patients with severe HeFH where inclisiran is the cornerstone of LDL management rather than an add-on, maintaining optimal hepatic function is especially important. This group may warrant more conservative curcumin limits and more frequent LFT monitoring.

What the Natural Medicines Database and Clinical Pharmacists Say

The Natural Medicines comprehensive database (formerly Natural Standard) rates the curcumin-anticoagulant combination as having "moderate" interaction potential, citing the antiplatelet mechanism and recommending monitoring for unusual bruising or bleeding [7]. There is no specific entry for curcumin plus inclisiran, because inclisiran is a novel agent and supplement-specific interaction studies have not been published.

Clinical pharmacists at major academic medical centers generally apply the following heuristic: if a supplement has known hepatotoxic potential or anticoagulant activity, and the patient's cardiovascular drug profile already involves liver-targeted agents or antiplatelet therapy, caution at doses above 1,000 mg/day is warranted, pending a formal review.

The Endocrine Society's 2023 position on dietary supplement use in cardiometabolic disease states: "Patients with established cardiovascular disease who wish to use botanical supplements should disclose all products to their clinicians, as pharmacodynamic interactions with cardiovascular drugs are underreported and underrecognized in clinical practice" [14].

Practical Guidance for Patients

These are the direct, actionable points based on the available evidence.

Dietary turmeric in cooking: Safe. The curcumin dose from culinary use is too low to produce clinically meaningful pharmacodynamic effects on coagulation or liver enzymes.

Curcumin supplements at 250-500 mg/day (standard dose, no piperine): Probably safe, but disclose to your prescriber and ensure a recent LFT panel is on file.

Curcumin supplements at 500-1,000 mg/day: Requires prescriber awareness. Check liver enzymes before continuing and at 3-month intervals. Review concurrent antiplatelet medications.

High-dose curcumin (above 1,000 mg/day) or piperine-enhanced formulations: Do not continue or start without explicit prescriber sign-off. Monitor LFTs every 6-8 weeks until stable. Avoid if ALT or AST is already above the normal range.

Timing: Because inclisiran is administered by injection in a clinic every 6 months, there is no practical dose-separation window the way there might be with an oral drug. Liver and platelet monitoring is a better protective strategy than timing.